Crystalline form
OwnerFritz Blatter, Martin Szelagiewicz +1inventors
InventorsFritz Blatter, Martin Szelagiewicz, Paul Adriaan Van Der Schaaf
Life of this patent
Estimating the term…
Abstract
The present invention is directed to the novel polymorphic Form F of Atorvastatin calcium, processes for the preparation therof and pharmaceutical compositions comprising this crystalline form.
Claims21
A crystalline polymorph F of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 24.3 (s), 10.2 (s), 8.6 (s), 4.57 (vs), 4.26 (m);
- wherein (vs)=very strong intensity;
- (s)=strong intensity;
- (m)=medium intensity.
A crystalline polymorph F of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 32.3 (w), 24.3 (s), 16.5 (m), 13.0 (w), 11.4 (m), 10.2 (s), 8.6 (s), 7.0 (m), 6.4 (m), 5.16 (m), 4.96 (m), 4.57 (vs), 4.26 (m), 3.95 (m), 3.67 (m), 3.48 (m), 3.20 (w);
- wherein (vs)=very strong intensity;
- (s)=strong intensity;
- (m)=medium intensity;
- (w)=weak intensity.
A crystalline polymorph F of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) having an X-ray powder diffraction pattern substantially as depicted in FIG. 1.
Dependencies are inferred from the claim text.